GlassScriptPhysician profile
Emily E Quinn
NPI 1881242840
$2,246.31
in general payments reported to CMS, 2019-2025
23 companies · $460 in 2025
The $460 reported for 2025 was more than what a typical Gerontology (Nurse Practitioner) provider received nationally (typical 2025 total: $180).
See the full distribution for Gerontology (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $505 · 2022: $490 · 2023: $517 · 2024: $275 · 2025: $460.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,252.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,251.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $438.63 | 2021-2025 | Opdivo, Reblozyl |
| Janssen Biotech, INC. | $232.30 | 2021-2025 | Carvykti, Rybrevant, Tecvayli |
| Beigene USA, INC. | $132.96 | 2024 | Brukinsa |
| Bayer Healthcare Pharmaceuticals INC. | $124.99 | 2023 | |
| Puma Biotechnology, INC. | $124.98 | 2023 | |
| Gilead Sciences, INC. | $121.83 | 2025 | |
| Celgene Corporation | $121.08 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $119.37 | 2022 | |
| Amgen INC. | $119.19 | 2021 | |
| Karyopharm Therapeutics INC. | $117.73 | 2023 | Xpovio |
| Astrazeneca Pharmaceuticals LP | $110.18 | 2022 | |
| Daiichi Sankyo INC. | $107.63 | 2022 | |
| Novartis Pharmaceuticals Corporation | $77.49 | 2024-2025 | |
| Exelixis INC. | $73.26 | 2022 | |
| Seagen INC. | $65.00 | 2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $31.72 | 2024-2025 | |
| Astellas Pharma US INC | $22.31 | 2024 | Xospata |
| Baxter Healthcare | $22.06 | 2024 | Preveleak |
| Blueprint Medicines Corporation | $19.05 | 2025 | Ayvakit |
| Taiho Oncology, INC. | $17.19 | 2024 | |
| Abbvie INC. | $17.17 | 2024 | |
| Pharmaessentia USA Corporation | $15.62 | 2024 | Besremi |
| Adaptive Biotechnologies Corporation | $14.57 | 2024 | Clonoseq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily Quinn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.